Vaccine adjuvant discovery program
Active Definitive Contract Awarded Last action
- Contract number
- 75N93024C00024
- Awardee
-
University Of Montana UEI DAY7Z8ZD48Q3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,433,656
Award facts
- Opportunity
-
- Vaccine adjuvant discovery program Pre-Solicitation · 75N93022R00022 · Posted Dec 5, 2022
- Contract value 55% obligated
-
- $5,433,656.00 Current, with exercised options
- $9,896,692.00 Potential, with all options
- Completion date 42% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 13 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Missoula, MT 59812, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,234,858 | |
| Change Order | $1,561,142 | |
| Other Administrative Action | $0 | |
| Original award | $1,637,656 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $9.9 million definitive contract to University of Montana for vaccine adjuvant discovery on September 30, 2024, with no set-aside applied and a ceiling extending through September 29, 2029.
The originating solicitation, posted December 5, 2022, calls for identification, characterization, and advancement of novel synthetic CLR-based adjuvants for use with bacterial and fungal antigens to induce safe and durable Th17 and/or Th17/Th1 immunity. University of Montana leads the discovery effort and coordinates subcontractors. The university is responsible for compounds library synthesis, structure-activity relationship studies, mechanism of action studies, receptor identification, early life immunity assessments, formulation, multivalent display, safety assessments, and immunogenicity studies.
Place of performance is Missoula, Montana. The contract is priced on a cost-no-fee basis.
Subcontractors include Inimmune Corp, which conducts high-throughput screening of compound libraries and medicinal chemistry support; University of Chicago, which provides M72 antigen and conducts murine vaccination and Mtb challenge studies; and University of Texas at San Antonio, which supplies fungal antigens and expertise in fungal disease models.
In FY2025, the contract invoiced $1.1 million across 2.2 FTEs and 4,586 contractor hours at a derived blended government-paid rate of $237.31 per hour, with 52 percent of contractor hours subcontracted out.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| The University Of Texas At San Antonio | $91,529 | |
| Inimmune Corp | $519,499 | |
| Inimmune Corp | $664,430 |
Quick answers
Who was awarded contract 75N93024C00024?
75N93024C00024 was awarded to University Of Montana by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2024.
How much is contract 75N93024C00024 worth?
The government has obligated $5,433,656 on 75N93024C00024. Its potential value, with all options, is $9,896,692.
Was contract 75N93024C00024 competed?
The extent of competition for 75N93024C00024 was full and open competition. The government received 13 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award